Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers

Shelly A. McNeil, Scott A. Halperin, Joanne M. Langley, Bruce Smith, Andrew Warren, Geoffrey P. Sharratt, Darlene M. Baxendale, Mark A. Reddish, Mary C. Hu, Steven D. Stroop, Janine Linden, Louis F. Fries, Peter E. Vink, James Dale

Research output: Contribution to journalArticle

207 Citations (Scopus)

Abstract

Background. Group A streptococcus (GAS) causes illness ranging from uncomplicated pharyngitis to life-threatening necrotizing fasciitis, toxic shock, and rheumatic fever. Attempts to develop an M protein-based vaccine have been hindered by the fact that some M proteins elicit both protective antibodies and antibodies that cross-react with human tissues. New molecular techniques have allowed the previous obstacles to be largely overcome. Methods. The vaccine is comprised of 4 recombinant proteins adsorbed to aluminum hydroxide that contain N-terminal peptides from streptococcal protective antigen and M proteins of 26 common pharyngitis, invasive, and/or rheumatogenic serotypes. Thirty healthy adult subjects received intramuscular 26-valent GAS vaccine (400 μg) at 0, 1, and 4 months, with clinical and laboratory follow-up for safety and immunogenicity using assays for tissue cross-reactive antibodies, type-specific M antibodies to 27 vaccine antigens, and functional (opsonization) activity of M protein antibodies. Results. The incidence of local reactogenicity was similar to that for other aluminum hydroxide-adsorbed vaccines in adults. No subject developed evidence of rheumatogenicity or nephritogenicity, and no induction of human tissue-reactive antibodies was detected. Overall, 26 of 27 antigenic peptides evoked a >4-fold increase in the geometric mean antibody titer over baseline. The mean log2 fold-increase in serum antibody titer (± standard error of the mean) for all 27 antigens was 3.67 ± 0.21. A significant mean log2 reduction in streptococcal bacterial counts in serum samples obtained after immunization was seen in opsonization assays for all M serotypes. Conclusions. On the basis of epidemiological data demonstrating that the majority of cases of pharyngitis, necrotizing fasciitis, and other invasive streptococcal infections are caused by a limited number of serotypes, this 26-valent vaccine could have significant impact on the overall burden of streptococcal disease.

Original languageEnglish (US)
Pages (from-to)1114-1122
Number of pages9
JournalClinical Infectious Diseases
Volume41
Issue number8
DOIs
StatePublished - Oct 15 2005

Fingerprint

Streptococcus
Healthy Volunteers
Vaccines
Safety
Antibodies
Pharyngitis
Necrotizing Fasciitis
Aluminum Hydroxide
Proteins
Antigens
Streptococcal Infections
Peptides
Rheumatic Fever
Bacterial Load
Septic Shock
Serum
Recombinant Proteins
Immunization
Incidence
Serogroup

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

McNeil, S. A., Halperin, S. A., Langley, J. M., Smith, B., Warren, A., Sharratt, G. P., ... Dale, J. (2005). Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clinical Infectious Diseases, 41(8), 1114-1122. https://doi.org/10.1086/444458

Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. / McNeil, Shelly A.; Halperin, Scott A.; Langley, Joanne M.; Smith, Bruce; Warren, Andrew; Sharratt, Geoffrey P.; Baxendale, Darlene M.; Reddish, Mark A.; Hu, Mary C.; Stroop, Steven D.; Linden, Janine; Fries, Louis F.; Vink, Peter E.; Dale, James.

In: Clinical Infectious Diseases, Vol. 41, No. 8, 15.10.2005, p. 1114-1122.

Research output: Contribution to journalArticle

McNeil, SA, Halperin, SA, Langley, JM, Smith, B, Warren, A, Sharratt, GP, Baxendale, DM, Reddish, MA, Hu, MC, Stroop, SD, Linden, J, Fries, LF, Vink, PE & Dale, J 2005, 'Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers', Clinical Infectious Diseases, vol. 41, no. 8, pp. 1114-1122. https://doi.org/10.1086/444458
McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clinical Infectious Diseases. 2005 Oct 15;41(8):1114-1122. https://doi.org/10.1086/444458
McNeil, Shelly A. ; Halperin, Scott A. ; Langley, Joanne M. ; Smith, Bruce ; Warren, Andrew ; Sharratt, Geoffrey P. ; Baxendale, Darlene M. ; Reddish, Mark A. ; Hu, Mary C. ; Stroop, Steven D. ; Linden, Janine ; Fries, Louis F. ; Vink, Peter E. ; Dale, James. / Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. In: Clinical Infectious Diseases. 2005 ; Vol. 41, No. 8. pp. 1114-1122.
@article{4d627106d5c345078282dceb8326473d,
title = "Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers",
abstract = "Background. Group A streptococcus (GAS) causes illness ranging from uncomplicated pharyngitis to life-threatening necrotizing fasciitis, toxic shock, and rheumatic fever. Attempts to develop an M protein-based vaccine have been hindered by the fact that some M proteins elicit both protective antibodies and antibodies that cross-react with human tissues. New molecular techniques have allowed the previous obstacles to be largely overcome. Methods. The vaccine is comprised of 4 recombinant proteins adsorbed to aluminum hydroxide that contain N-terminal peptides from streptococcal protective antigen and M proteins of 26 common pharyngitis, invasive, and/or rheumatogenic serotypes. Thirty healthy adult subjects received intramuscular 26-valent GAS vaccine (400 μg) at 0, 1, and 4 months, with clinical and laboratory follow-up for safety and immunogenicity using assays for tissue cross-reactive antibodies, type-specific M antibodies to 27 vaccine antigens, and functional (opsonization) activity of M protein antibodies. Results. The incidence of local reactogenicity was similar to that for other aluminum hydroxide-adsorbed vaccines in adults. No subject developed evidence of rheumatogenicity or nephritogenicity, and no induction of human tissue-reactive antibodies was detected. Overall, 26 of 27 antigenic peptides evoked a >4-fold increase in the geometric mean antibody titer over baseline. The mean log2 fold-increase in serum antibody titer (± standard error of the mean) for all 27 antigens was 3.67 ± 0.21. A significant mean log2 reduction in streptococcal bacterial counts in serum samples obtained after immunization was seen in opsonization assays for all M serotypes. Conclusions. On the basis of epidemiological data demonstrating that the majority of cases of pharyngitis, necrotizing fasciitis, and other invasive streptococcal infections are caused by a limited number of serotypes, this 26-valent vaccine could have significant impact on the overall burden of streptococcal disease.",
author = "McNeil, {Shelly A.} and Halperin, {Scott A.} and Langley, {Joanne M.} and Bruce Smith and Andrew Warren and Sharratt, {Geoffrey P.} and Baxendale, {Darlene M.} and Reddish, {Mark A.} and Hu, {Mary C.} and Stroop, {Steven D.} and Janine Linden and Fries, {Louis F.} and Vink, {Peter E.} and James Dale",
year = "2005",
month = "10",
day = "15",
doi = "10.1086/444458",
language = "English (US)",
volume = "41",
pages = "1114--1122",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers

AU - McNeil, Shelly A.

AU - Halperin, Scott A.

AU - Langley, Joanne M.

AU - Smith, Bruce

AU - Warren, Andrew

AU - Sharratt, Geoffrey P.

AU - Baxendale, Darlene M.

AU - Reddish, Mark A.

AU - Hu, Mary C.

AU - Stroop, Steven D.

AU - Linden, Janine

AU - Fries, Louis F.

AU - Vink, Peter E.

AU - Dale, James

PY - 2005/10/15

Y1 - 2005/10/15

N2 - Background. Group A streptococcus (GAS) causes illness ranging from uncomplicated pharyngitis to life-threatening necrotizing fasciitis, toxic shock, and rheumatic fever. Attempts to develop an M protein-based vaccine have been hindered by the fact that some M proteins elicit both protective antibodies and antibodies that cross-react with human tissues. New molecular techniques have allowed the previous obstacles to be largely overcome. Methods. The vaccine is comprised of 4 recombinant proteins adsorbed to aluminum hydroxide that contain N-terminal peptides from streptococcal protective antigen and M proteins of 26 common pharyngitis, invasive, and/or rheumatogenic serotypes. Thirty healthy adult subjects received intramuscular 26-valent GAS vaccine (400 μg) at 0, 1, and 4 months, with clinical and laboratory follow-up for safety and immunogenicity using assays for tissue cross-reactive antibodies, type-specific M antibodies to 27 vaccine antigens, and functional (opsonization) activity of M protein antibodies. Results. The incidence of local reactogenicity was similar to that for other aluminum hydroxide-adsorbed vaccines in adults. No subject developed evidence of rheumatogenicity or nephritogenicity, and no induction of human tissue-reactive antibodies was detected. Overall, 26 of 27 antigenic peptides evoked a >4-fold increase in the geometric mean antibody titer over baseline. The mean log2 fold-increase in serum antibody titer (± standard error of the mean) for all 27 antigens was 3.67 ± 0.21. A significant mean log2 reduction in streptococcal bacterial counts in serum samples obtained after immunization was seen in opsonization assays for all M serotypes. Conclusions. On the basis of epidemiological data demonstrating that the majority of cases of pharyngitis, necrotizing fasciitis, and other invasive streptococcal infections are caused by a limited number of serotypes, this 26-valent vaccine could have significant impact on the overall burden of streptococcal disease.

AB - Background. Group A streptococcus (GAS) causes illness ranging from uncomplicated pharyngitis to life-threatening necrotizing fasciitis, toxic shock, and rheumatic fever. Attempts to develop an M protein-based vaccine have been hindered by the fact that some M proteins elicit both protective antibodies and antibodies that cross-react with human tissues. New molecular techniques have allowed the previous obstacles to be largely overcome. Methods. The vaccine is comprised of 4 recombinant proteins adsorbed to aluminum hydroxide that contain N-terminal peptides from streptococcal protective antigen and M proteins of 26 common pharyngitis, invasive, and/or rheumatogenic serotypes. Thirty healthy adult subjects received intramuscular 26-valent GAS vaccine (400 μg) at 0, 1, and 4 months, with clinical and laboratory follow-up for safety and immunogenicity using assays for tissue cross-reactive antibodies, type-specific M antibodies to 27 vaccine antigens, and functional (opsonization) activity of M protein antibodies. Results. The incidence of local reactogenicity was similar to that for other aluminum hydroxide-adsorbed vaccines in adults. No subject developed evidence of rheumatogenicity or nephritogenicity, and no induction of human tissue-reactive antibodies was detected. Overall, 26 of 27 antigenic peptides evoked a >4-fold increase in the geometric mean antibody titer over baseline. The mean log2 fold-increase in serum antibody titer (± standard error of the mean) for all 27 antigens was 3.67 ± 0.21. A significant mean log2 reduction in streptococcal bacterial counts in serum samples obtained after immunization was seen in opsonization assays for all M serotypes. Conclusions. On the basis of epidemiological data demonstrating that the majority of cases of pharyngitis, necrotizing fasciitis, and other invasive streptococcal infections are caused by a limited number of serotypes, this 26-valent vaccine could have significant impact on the overall burden of streptococcal disease.

UR - http://www.scopus.com/inward/record.url?scp=26444487581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444487581&partnerID=8YFLogxK

U2 - 10.1086/444458

DO - 10.1086/444458

M3 - Article

VL - 41

SP - 1114

EP - 1122

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 8

ER -